Navigation Links
Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Date:1/5/2012

DEERFIELD, Ill., Jan. 5, 2012 /PRNewswire/ -- Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.  BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.

The Phase I trial is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A.  When used for prophylaxis, Baxter's ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes.  This Phase I trial is the first step in assessing whether BAX 855 can be infused less frequently. 

"This trial is designed to provide new insights about our investigational longer-acting FVIII molecule, BAX 855, with the ultimate goal of improving care for patients living with hemophilia A," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business. "The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE."

BAX 855 employs Baxter's proprietary full-length plasma/albumin-free recombinant protein platform that does not contain any human or animal-derived additives. BAX 855 leverages Nektar Therapeutics' (NASDAQ: NKTR) proprietary PEGylation technology, which is designed to extend the duration of activity of proteins and larger molecules.  Baxter and Nektar have a collaboration to develop PEGylated products designed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
2. Variation Biotechnologies Names Jeff Baxter CEO
3. Baxter International First Quarter 2009 Financial Results Conference Call
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
7. AmeriCares Presents Power of Partnership Award to Baxter
8. Baxter International Third Quarter 2008 Financial Results Conference Call
9. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
10. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
11. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Research and Markets  has announced the addition of ... Chromatograph Market by Type , Technology, Spectroscopy, Gas chromatography, ... to 2013 - 2020" report to their offering. ... analytical instrument that provides chemical composition data on process ... which companies carry out their production and improve the ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... 2014  The 12th Cold Chain GDP & ... September 29 at the John B. Hynes Convention Center. ... for a weeklong conference attracting industry executives ... is designed to cover the industry,s most pressing topics, ... all temperature range products, GDP compliance requirements and supply ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 212th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... KYOTO, Japan and MARCY L,ETOILE, France , ... today that they have entered into a partnership to ... microbiology laboratories. bioMerieux will work with Shimadzu and their ... spectrometry technology for optimized integration into the microbiology laboratory ...
... , May 21 Micromet, Inc. (Nasdaq: MITI ... next-generation antibodies for the treatment of cancer, today announced that updates ... at two upcoming medical conferences. , ... Blinatumomab (MT103), the Company,s lead product candidate, will ...
... , BRISBANE, Calif. , May 21 InterMune, Inc. (Nasdaq: ... Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at ... May 26 at 3 p.m. EDT . , ... To access a live audio webcast of the presentation, investors ...
Cached Biology Technology:Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 2Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 3Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 4Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 2Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 3InterMune to Present at 2010 Citi Health Care Conference 2
(Date:9/29/2014)... inhibitor dabrafenib has significant anti-tumour activity in patients ... cancer whose disease has progressed after chemotherapy, according ... 2014 Congress in Madrid, Spain. , "Reports ... generated considerable interest because these mutations may be ... agents," says lead author Dr David Planchard, pulmonary ...
(Date:9/29/2014)... in French . ... of days an expectant mother was deprived of electricity ... of her child, a new study finds., Scientists from ... have detected a distinctive ,signature, in the DNA of ... ice storm. Five months after the event, researchers recruited ...
(Date:9/29/2014)... a previously unknown mechanism by which estrogen prepares ... of estrogen-positive breast cancers, resist cancer drugs. The ... breast cancer therapy and will help doctors predict ... The University of Illinois team reports its findings ... pre-activates the unfolded-protein response (UPR), a pathway that ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... world over, are hungry for more meat, milk and ... has prompted explosive growth in livestock production and massive ... new textbook, Animal Manure Recycling: Treatment and Management, draws ... to put environmental problems to work and ensure the ...
... Department of Energy is making good on the second phase of ... study led by Dr. Joshua Yuan, Texas A&M AgriLife Research plant ... Yuan, who was granted $1.8 million for Phase I ... potential fuel source., The scientist said his research is moving ahead ...
... a new model for a genetic eye disease, and shows ... monkeys can yield valuable information about the human brain. ... of the Society for Neuroscience and the world,s largest source ... models have long been central in how we understand the ...
Cached Biology News:New textbook tackles the sustainable recycling of manure 2Plant fuel project moves to second phase under US Energy Department grant 2Understanding ourselves by studying the animal kingdom 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Biology Products: